

Supplementary Table 4. Treatment-emergent adverse events occurring in ≥20% of patients

All patients, <i>n</i> = 69		
	Any grade	Grades 3/4
≥1 TEAE, <i>n</i> (%)	69 (100)	40 (58.0)
Hematologic		
Thrombocytopenia	35 (50.7)	9 (13.0)
Gastrointestinal		
Nausea/vomiting	45 (65.2)	0
Diarrhea	29 (42.0)	1 (1.4)
Stomatitis	17 (24.6)	0
Other		
Fatigue/asthenia	44 (63.8)	6 (8.7)
Dysgeusia	20 (29.0)	0
Decreased appetite	16 (23.2)	0
Hyperglycemia	15 (21.7)	4 (5.8)

TEAE, treatment-emergent adverse event.